BIOXYTRAN Warns of Going-Concern as Cash Near Zero, Heavy Debt and Dilution Loom

BIOXYTRAN, Inc. (PINK: BIXT)

Quick take: management is advancing R&D and clinical programs while running critically low on cash. The quarter produced a small GAAP profit driven by a favorable mark-to-market on an embedded derivative, but the balance sheet shows large liabilities, heavy potential dilution and a going-concern warning.

Key facts & statistics
- Cash: $3,144 (June 30, 2025).
- Total assets: $147,501; Intangibles, net: $144,357 (up from $133,540 at 12/31/24).
- Total current liabilities: $2,782,771 (was $1,930,642 at 12/31/24).
- Convertible note principal: $805,000; accrued interest: $204,911; total amount due on note: $1,009,911.
- Embedded derivative liability: $684,002 (was $186,652 on 12/31/24).
- Stockholders' deficit: $(2,635,270). Accumulated deficit: $(20,239,366).
- Common shares outstanding: 88,992,243; Preferred shares outstanding: 43,429,639.
- Net (profit) / loss: three months ended 6/30/25 = $35,437 (profit); six months ended 6/30/25 = $(1,318,197) loss.
- Weighted average common shares (six months): 88,940,600.
- R&D expense (six months): $452,000 (vs $27,000 prior-year).
- Total operating expenses (six months): $739,220.
- Stock-based compensation (six months): $69,061 (incl. $27,795 to affiliates).
- Net cash used in operating activities (six months): $(248,010); financing provided: $261,177 (loans from affiliates).
- Net working capital: $(2,779,627). Management estimates need of $3,700,000 to fund ~15 months of operations and says current cash is insufficient beyond July 2025.
- Material weakness: disclosure controls and internal control over financial reporting were not effective as of 6/30/25.

What's happening inside the company (straightforward)
- R&D ramp: the company increased clinical and development spending (AOC BXT-25 work and clinical costs) - R&D rose to $452k for the six months.
- IP capitalization: capitalized patent/prosecution costs increased intangible assets to $144,357 (no impairment recorded).
- Aggressive financing & equity activity: frequent debt conversions, issuance of shares under the 2021 Plan, and affiliate loans are being used to bridge cash needs.
- Management actions: officers forfeited payroll ($941,890 total forfeiture; $214,780 was prior-year accrual) which materially reduced payroll expense near-term and was recognized against paid-in capital in part.
- Controls: small finance team, identified material weaknesses; consultant hired but additional qualified accounting personnel still needed.

Income statement - positives
- GAAP improvement in the quarter: three-month period 6/30/25 reported a $35,437 net profit (driven by a $307,402 favorable change in fair value of the embedded derivative).
- R&D investment increased (consistent with clinical progress and IND activity noted in MD&A).
- Operating expense discipline in G&A vs prior year: some promotional and payroll costs were reduced (partly due to payroll forfeiture).

Income statement - negatives / risks
- Six-month net loss of $(1,318,197) - core operating loss remains large for the period.
- The quarter's profit is non-recurring and driven by fair-value accounting on a derivative (volatile and reversible).
- High interest/finance costs: interest and debt-related charges remain notable (interest expense and amortization items).
- Stock-based compensation still material ($69k for six months) and ongoing share issuance has diluted equity base.
- No revenues: company remains pre-revenue and dependent on financing; revenue line = $0.

Balance sheet & dilution risks
- Cash runway is effectively exhausted ($3,144). Management says current cash will not fund operations past July 2025 without new capital.
- Large convertible note + embedded derivative creates both balance-sheet volatility and potential dilution (note convertible features cited could require issuing millions of shares depending on market prices). The filing references potential issuance of ~12,623,887 shares upon conversion at the market price example and that Convertible Preferred class could convert into 217,148,195 common-share equivalents.
- Total current liabilities ($2.78M) far exceed current assets ($3,144) - negative working capital $(2.78M).

Near-term catalysts & watch items
- Clinical updates: IND/trial results for ProLectin and BXT-25 animal/tox studies and the India Phase 1b/2a COVID trial; publishings and FDA/ CDSCO trial starts are value-driving milestones.
- Financing progress: management intends private placements (noted intent for ~ $2M Reg D offering and general target of $3.7M) - success and pricing will determine survival and dilution.
- Convertible note / derivative revaluations: further fair-value swings on the embedded derivative can flip GAAP profit/loss and affect equity/liability balances.
- Internal control remediation: hiring qualified accounting staff and fixing segregation of duties - unresolved control weakness increases reporting risk.

Bottom line: BIOXYTRAN is a clinical-stage, pre-revenue biotech investing in R&D and IP but is financially stressed - extremely low cash, heavy near-term liabilities, and significant dilution risk from convertible instruments. Positive operational signs (R&D, IP activity, IND/trial milestones) are offset by a going-concern warning, large liabilities, and a dependency on successful near-term financing.

Sources: BIOXYTRAN, Inc. Form 10‑Q for quarter ended June 30, 2025 (figures and disclosures as reported).